acute retinal necrosis syndrome
Conditions
Interventions
one:Minimally invasive vitreous surgery
two:Systemic antiviral therapy
Sponsors
The First Affiliated Hospital of Army Medical University,PLA
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients = 18 years old, male or female, voluntarily participate, patients and their families agree and sign an informed consent form, can abide by the research or follow-up process, and can cooperate in observing adverse events and efficacy; 2. Acute retinal necrosis syndrome is diagnosed by professional ophthalmologists: ARN is usually diagnosed based on clinical characteristics; According to the ARN diagnostic criteria of the American Academy of Ophthalmology (1994), 1) there is one or more necrotic lesions in one side of the retina with clear boundary; 2) The disease progressed rapidly without antiviral treatment; 3) The lesion presented circumferential progression; 4) Occlusive retinopathy mainly affects arterioles; 5) Obvious vitreous and/or anterior chamber inflammatory reaction; 6) For atypical cases or cases with difficult diagnosis, if the clinical features are insufficient to support the diagnosis, the diagnosis can be confirmed by examining aqueous humor or vitreous cavity fluid samples. 3. There was no retinal detachment or tear in the affected eye at the time of treatment. 4. Visual acuity = 0.5, or vitreous opacity =++, or the focus is close to retinal area I (area I is defined as a circular area with the optic papilla as the center and the distance from the optic papilla to the macular fovea twice as the radius). 5. If the disease is bilateral, choose the eyes with severe vitreous opacity for minimally invasive vitreous surgery.
Exclusion criteria
Exclusion criteria: 1. Eye condition: 1) Vitrectomy has been performed on the study eye for various reasons. 2) The study eye has other diseases that may affect the interpretation of the study results or may cause visual impairment or require medical or surgical intervention within the 6-month treatment period. 3) Other non viral infectious diseases of the eye that have not been cured; To study patients with eye diseases that may affect vision; Patients with eye surgery within 1 month of the study eye; Uncontrolled glaucoma patients. 2. General condition or treatment: 1) HIV and other patients with systemic immunodeficiency; 2) Pregnant and lactating women, people with drug allergy history, people with liver and kidney dysfunction, people with cardiopulmonary dysfunction, people with uncontrolled systemic diseases; 3) Those who have abnormal coagulation function or are currently using anticoagulant drugs (such as aspirin); 4) Stroke, coronary heart disease, history of angina pectoris and renal insufficiency require dialysis or renal transplantation, as well as other systemic chronic diseases that are not suitable for clinical trials; 5) At present or in the near future, it may be necessary to use drugs known to be toxic to the lens, retina or optic nerve, including chloroquine/hydroxychloroquine, phenothiazine, ethambutol, desferrimin and tamoxifen. 3. Compliance: 1) Cases who can not cooperate in the observation of adverse events and efficacy and have poor compliance with the test; 2) Failure to follow the study or follow-up process.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| best corrected visual acuity; | — |
Countries
China
Contacts
Public ContactYong Liu
The First Affiliated Hospital of Army Medical University,PLA
Outcome results
None listed